SK18922000A3 - Terapeutick kombincie obsahujce selektvny modultor receptorov estrognu a hormn prittnych teliesok - Google Patents

Terapeutick kombincie obsahujce selektvny modultor receptorov estrognu a hormn prittnych teliesok Download PDF

Info

Publication number: SK18922000A3
Authority: SK; Slovakia
Prior art keywords: phenyl; compound; bone; cis; ethoxy
Prior art date: 1998-06-16

Application number

SK1892-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Hua Zhu Ke

David Duane Thompson

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-16

Filing date

1999-05-26

Publication date

2001-09-11

1999-05-26 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2001-09-11 Publication of SK18922000A3 publication Critical patent/SK18922000A3/sk

Links

108090000445 Parathyroid hormone Proteins 0.000 title claims abstract description 47
102000003982 Parathyroid hormone Human genes 0.000 title claims abstract description 46
239000000199 parathyroid hormone Substances 0.000 title claims abstract description 46
229960001319 parathyroid hormone Drugs 0.000 title claims abstract description 46
229940095743 selective estrogen receptor modulator Drugs 0.000 title description 5
239000000333 selective estrogen receptor modulator Substances 0.000 title description 5
230000001225 therapeutic effect Effects 0.000 title description 3
238000000034 method Methods 0.000 claims abstract description 61
210000000988 bone and bone Anatomy 0.000 claims abstract description 55
208000001132 Osteoporosis Diseases 0.000 claims abstract description 31
239000000203 mixture Substances 0.000 claims abstract description 20
150000003839 salts Chemical class 0.000 claims abstract description 20
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 claims abstract description 19
239000012634 fragment Substances 0.000 claims abstract description 15
150000001875 compounds Chemical class 0.000 claims description 69
241000124008 Mammalia Species 0.000 claims description 28
238000011282 treatment Methods 0.000 claims description 24
206010065687 Bone loss Diseases 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 15
239000002552 dosage form Substances 0.000 claims description 14
241000282414 Homo sapiens Species 0.000 claims description 13
208000010392 Bone Fractures Diseases 0.000 claims description 11
239000003085 diluting agent Substances 0.000 claims description 10
230000035876 healing Effects 0.000 claims description 10
INEHJXCWEVNEDZ-LUDNRVPPSA-N (2s,3s)-2,3-dihydroxybutanedioic acid;(5r,6s)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 INEHJXCWEVNEDZ-LUDNRVPPSA-N 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
230000001737 promoting effect Effects 0.000 claims description 6
-1 4- (2-pyrrolidin-1-yl-ethoxy) -phenyl Chemical group 0.000 claims description 5
201000001245 periodontitis Diseases 0.000 claims description 5
201000010814 Synostosis Diseases 0.000 claims description 4
238000004806 packaging method and process Methods 0.000 claims description 4
230000001939 inductive effect Effects 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
230000008093 supporting effect Effects 0.000 claims description 2
230000006698 induction Effects 0.000 claims 2
JWQYZECMEPOAPF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1=CC=C2CC(O)CCC2=C1 JWQYZECMEPOAPF-UHFFFAOYSA-N 0.000 claims 1
YLNJLHNNGALZBC-UHFFFAOYSA-N C1CCC2=C(C(=CC(=C2C1)OCCN3CCCC3)O)C4=CC=CC=C4 Chemical compound C1CCC2=C(C(=CC(=C2C1)OCCN3CCCC3)O)C4=CC=CC=C4 YLNJLHNNGALZBC-UHFFFAOYSA-N 0.000 claims 1
229940088597 hormone Drugs 0.000 claims 1
239000005556 hormone Substances 0.000 claims 1
210000002990 parathyroid gland Anatomy 0.000 claims 1
208000001164 Osteoporotic Fractures Diseases 0.000 abstract description 4
208000036119 Frailty Diseases 0.000 abstract 2
206010003549 asthenia Diseases 0.000 abstract 2
241000700159 Rattus Species 0.000 description 19
230000000694 effects Effects 0.000 description 17
229940011871 estrogen Drugs 0.000 description 14
239000000262 estrogen Substances 0.000 description 14
239000002775 capsule Substances 0.000 description 13
230000011164 ossification Effects 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
206010017076 Fracture Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
208000006386 Bone Resorption Diseases 0.000 description 5
230000024279 bone resorption Effects 0.000 description 5
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000002265 prevention Effects 0.000 description 4
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000003263 anabolic agent Substances 0.000 description 3
229940124325 anabolic agent Drugs 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
239000011888 foil Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
150000004677 hydrates Chemical class 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
239000011707 mineral Substances 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
230000008520 organization Effects 0.000 description 3
239000002985 plastic film Substances 0.000 description 3
229960004622 raloxifene Drugs 0.000 description 3
238000011084 recovery Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
208000020084 Bone disease Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
206010014733 Endometrial cancer Diseases 0.000 description 2
206010014759 Endometrial neoplasm Diseases 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
206010020100 Hip fracture Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000029725 Metabolic bone disease Diseases 0.000 description 2
206010049088 Osteopenia Diseases 0.000 description 2
241000218657 Picea Species 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000006187 pill Substances 0.000 description 2
229940077150 progesterone and estrogen Drugs 0.000 description 2
229940089617 risedronate Drugs 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000002303 tibia Anatomy 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241000282339 Mustela Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
206010046782 Uterine enlargement Diseases 0.000 description 1
206010048049 Wrist fracture Diseases 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000010072 bone remodeling Effects 0.000 description 1
230000008416 bone turnover Effects 0.000 description 1
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
230000010036 cardiovascular benefit Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229950004203 droloxifene Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical class OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
230000006883 memory enhancing effect Effects 0.000 description 1
230000009245 menopause Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960002378 oftasceine Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
244000144977 poultry Species 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
206010041569 spinal fracture Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Physical Education & Sports Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)

SK1892-2000A 1998-06-16 1999-05-26 Terapeutick kombincie obsahujce selektvny modultor receptorov estrognu a hormn prittnych teliesok SK18922000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8947998P	1998-06-16	1998-06-16
PCT/IB1999/000949 WO1999065482A1 (en)	1998-06-16	1999-05-26	Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone

Publications (1)

Publication Number	Publication Date
SK18922000A3 true SK18922000A3 (sk)	2001-09-11

Family

ID=22217879

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1892-2000A SK18922000A3 (sk)	1998-06-16	1999-05-26	Terapeutick kombincie obsahujce selektvny modultor receptorov estrognu a hormn prittnych teliesok

Country Status (34)

Country	Link
US (1)	US6132774A (is)
EP (1)	EP1094808A1 (is)
JP (1)	JP2002518323A (is)
KR (1)	KR20010052818A (is)
CN (1)	CN1305373A (is)
AP (1)	AP9901580A0 (is)
AR (1)	AR018867A1 (is)
AU (1)	AU3725999A (is)
BG (1)	BG105125A (is)
BR (1)	BR9911228A (is)
CA (1)	CA2335078A1 (is)
CO (1)	CO5070584A1 (is)
EA (1)	EA200001199A1 (is)
GT (1)	GT199900066A (is)
HN (1)	HN1999000063A (is)
HR (1)	HRP20000858A2 (is)
HU (1)	HUP0102759A3 (is)
ID (1)	ID26873A (is)
IL (1)	IL139588A0 (is)
IS (1)	IS5719A (is)
MA (1)	MA26649A1 (is)
NO (1)	NO20006313L (is)
NZ (1)	NZ508039A (is)
OA (1)	OA11566A (is)
PA (1)	PA8471201A1 (is)
PE (1)	PE20000644A1 (is)
PL (1)	PL344982A1 (is)
SK (1)	SK18922000A3 (is)
TN (1)	TNSN99119A1 (is)
TR (1)	TR200003567T2 (is)
UA (1)	UA60367C2 (is)
WO (1)	WO1999065482A1 (is)
YU (1)	YU75800A (is)
ZA (1)	ZA993972B (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN1996000101A (es) *	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis
US20020107230A1 (en) *	2000-12-22	2002-08-08	Waldon R. Forrest	Methods and formulations for the treatment of female sexual dysfunction
US20030191096A1 (en) *	2002-04-03	2003-10-09	Leonard Thomas W.	Method of hormonal therapy
JP2007512359A (ja)	2003-11-19	2007-05-17	メタバシス・セラピューティクス・インコーポレイテッド	新規なリン含有甲状腺ホルモン様物質
MX2007005137A (es) *	2004-11-23	2007-06-22	Warner Lambert Co	Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
US7790745B2 (en)	2005-10-21	2010-09-07	Bristol-Myers Squibb Company	Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
WO2008070496A2 (en)	2006-12-01	2008-06-12	Bristol-Myers Squibb Company	N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20120046364A1 (en)	2009-02-10	2012-02-23	Metabasis Therapeutics, Inc.	Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
TW201043595A (en) *	2009-03-13	2010-12-16	Organon Nv	Tetrahydronaphthalen-2-ol derivatives
DE102010027016A1 (de)	2010-07-09	2012-01-12	Universitätsklinikum Jena	Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
CN111067907A (zh) *	2018-10-18	2020-04-28	常州大学	孕激素在抑制血管内皮生长因子表达中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5254595A (en) *	1988-12-23	1993-10-19	Elf Sanofi	Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
TW432073B (en) *	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
HN1996000101A (es) *	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis

1999
- 1999-04-29 PA PA19998471201A patent/PA8471201A1/es unknown
- 1999-05-03 HN HN1999000063A patent/HN1999000063A/es unknown
- 1999-05-10 GT GT199900066A patent/GT199900066A/es unknown
- 1999-05-26 WO PCT/IB1999/000949 patent/WO1999065482A1/en not_active Ceased
- 1999-05-26 JP JP2000554362A patent/JP2002518323A/ja active Pending
- 1999-05-26 NZ NZ508039A patent/NZ508039A/xx unknown
- 1999-05-26 OA OA1200000340A patent/OA11566A/en unknown
- 1999-05-26 CA CA002335078A patent/CA2335078A1/en not_active Abandoned
- 1999-05-26 UA UA2000127244A patent/UA60367C2/uk unknown
- 1999-05-26 IL IL13958899A patent/IL139588A0/xx unknown
- 1999-05-26 BR BR9911228-0A patent/BR9911228A/pt not_active IP Right Cessation
- 1999-05-26 PL PL99344982A patent/PL344982A1/xx unknown
- 1999-05-26 AU AU37259/99A patent/AU3725999A/en not_active Abandoned
- 1999-05-26 HR HR20000858A patent/HRP20000858A2/hr not_active Application Discontinuation
- 1999-05-26 KR KR1020007014141A patent/KR20010052818A/ko not_active Ceased
- 1999-05-26 CN CN99807345A patent/CN1305373A/zh active Pending
- 1999-05-26 TR TR2000/03567T patent/TR200003567T2/xx unknown
- 1999-05-26 YU YU75800A patent/YU75800A/sh unknown
- 1999-05-26 SK SK1892-2000A patent/SK18922000A3/sk unknown
- 1999-05-26 ID IDW20002626A patent/ID26873A/id unknown
- 1999-05-26 EA EA200001199A patent/EA200001199A1/ru unknown
- 1999-05-26 HU HU0102759A patent/HUP0102759A3/hu unknown
- 1999-05-26 US US09/424,010 patent/US6132774A/en not_active Expired - Fee Related
- 1999-05-26 EP EP99919491A patent/EP1094808A1/en not_active Withdrawn
- 1999-06-10 AP APAP/P/1999/001580A patent/AP9901580A0/en unknown
- 1999-06-14 PE PE1999000526A patent/PE20000644A1/es not_active Application Discontinuation
- 1999-06-15 ZA ZA9903972A patent/ZA993972B/xx unknown
- 1999-06-15 AR ARP990102846A patent/AR018867A1/es not_active Application Discontinuation
- 1999-06-15 MA MA25623A patent/MA26649A1/fr unknown
- 1999-06-15 TN TNTNSN99119A patent/TNSN99119A1/fr unknown
- 1999-06-16 CO CO99037623A patent/CO5070584A1/es unknown
2000
- 2000-11-21 IS IS5719A patent/IS5719A/is unknown
- 2000-12-12 NO NO20006313A patent/NO20006313L/no not_active Application Discontinuation
2001
- 2001-01-08 BG BG105125A patent/BG105125A/xx unknown

Also Published As

Publication number	Publication date
PE20000644A1 (es)	2000-08-02
NZ508039A (en)	2003-03-28
HRP20000858A2 (en)	2001-10-31
KR20010052818A (ko)	2001-06-25
PA8471201A1 (es)	2000-09-29
IS5719A (is)	2000-11-21
AR018867A1 (es)	2001-12-12
WO1999065482A1 (en)	1999-12-23
PL344982A1 (en)	2001-11-19
YU75800A (sh)	2003-12-31
AU3725999A (en)	2000-01-05
OA11566A (en)	2004-05-26
GT199900066A (es)	2000-10-31
ID26873A (id)	2001-02-15
BG105125A (en)	2001-11-30
CO5070584A1 (es)	2001-08-28
US6132774A (en)	2000-10-17
CN1305373A (zh)	2001-07-25
JP2002518323A (ja)	2002-06-25
NO20006313D0 (no)	2000-12-12
TR200003567T2 (tr)	2001-06-21
HUP0102759A2 (hu)	2002-03-28
TNSN99119A1 (fr)	2005-11-10
IL139588A0 (en)	2002-02-10
BR9911228A (pt)	2001-02-13
HUP0102759A3 (en)	2002-12-28
HN1999000063A (es)	2000-01-12
AP9901580A0 (en)	1999-06-30
ZA993972B (en)	2000-12-15
EP1094808A1 (en)	2001-05-02
MA26649A1 (fr)	2004-12-20
CA2335078A1 (en)	1999-12-23
UA60367C2 (uk)	2003-10-15
EA200001199A1 (ru)	2001-04-23
NO20006313L (no)	2000-12-12

Publication	Publication Date	Title
Muñoz-Torres et al.	2004	Calcitonin therapy in osteoporosis
RU2636498C2 (ru)	2017-11-23	Способы лечения и/или подавления прироста массы
US7030157B2 (en)	2006-04-18	Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
EP1118323A2 (en)	2001-07-25	Method of reducing morbidity and the risk of mortality
SK18922000A3 (sk)	2001-09-11	Terapeutick kombincie obsahujce selektvny modultor receptorov estrognu a hormn prittnych teliesok
JP2001220357A (ja)	2001-08-14	Ｅｐ２／ｅｐ４レセプター選択アゴニストによる骨粗鬆症の治療
US6284773B1 (en)	2001-09-04	Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
SK18912000A3 (sk)	2001-10-08	Terapeutické kombinácie obsahujúce selektívny modulátor receptorov estrogénu (serm) a sekretagogum rastového hormónu (ghs) nanie muskuloskeletárnej slabosti
SK18902000A3 (sk)	2001-12-03	Terapeutické kombinácie (selektívnych) modulátorov estrogénneho receptora (serm) a prostriedkov podporujúcich sekréciu rastového hormónu (ghs) na liečbu muskuloskeletárnej fragility
Dempster et al.	2006	Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis
CZ20004678A3 (cs)	2001-05-16	Terapeutické kombinace obsahující selektivní modulátor receptorů estrogenů a hormon příštítných tělísek
MXPA00012728A (en)	2001-07-31	Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
Keam et al.	2004	Prevention and treatment of osteoporosis in postmenopausal women: defining the role of alendronate
HK1035666A (en)	2001-12-07	Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
CZ20004679A3 (cs)	2001-05-16	Terapeutické kombinace (selektivních) modulátorů estrogenního receptoru (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
MXPA99005564A (en)	2000-11-01	Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
AU2002300896B2 (en)	2006-03-30	Method of enhancing bone mineral density
Chesnut III et al.	2003	Clinical Utilization of Salmon Calcitonin in the Treatment of Osteoporosis: Rationale, Supportive Data, and Considerations for the Future
Sirsikar et al.	2015	Prevention and Management of Postmenopausal Osteoporosis
CZ20004680A3 (cs)	2001-06-13	Terapeutické kombinace (selektivních) modulátorů estrogenního receptorů (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
MXPA00012727A (en)	2001-07-31	Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty